Pubblicazioni

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

2018 - NEW ENGLAND JOURNAL OF MEDICINE

Mateos, M. -V.; Dimopoulos, M. A.; Cavo, M.; Suzuki, K.; Jakubowiak, A.; Knop, S.; Doyen, C.; Lucio, P.; Nagy, Z.; Kaplan, P.; Pour, L.; Cook, M.; Grosicki, S.; Crepaldi, A.; Liberati, A. M.; Campbell, P.; Shelekhova, T.; Yoon, S. -S.; Iosava, G.; Fujisaki, T.; Garg, M.; Chiu, C.; Wang, J.; Carson, R.; Crist, W.; Deraedt, W.; Nguyen, H.; Qi, M.; San-Miguel, J.; Foa, R.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4). A double-blind, multicentre, phase 3, randomised, placebo-controlled trial

2015 - THE LANCET ONCOLOGY

Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C; Hart, Lowell L; Jones, Robert; Mcdermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; Maclean, David B; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I; Dreicer, Robert; Webb, Iain J; de Wit, Ronald; Collaborators, ; Tubaro, Andrea